Chemical Supplier Chemical Manufacturer Connect

Pharma R&D Chem invites world wide pharmacuticals chemical manufactures for Free product registration.

To enhance your products marketing, we are helping all pharma chem and R&D companies with Free internet marketing with SeachEngineMerketing*.

  

 

Suven Life Sciences Ltd announced that it has completed the Phase-I single ascending dose study of SUVN-502 in healthy subjects. SUVN-502 is a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson, Schizophrenia. 

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally discovered therapeutic drug candidates currently in clinical and pre-clinical stage of development targeting conditions such as ADHD, dementia, and depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.;

Suven Life Sciences also creates Advanced Intermediates and API 's

By studying the variety of chemical substances and their structures recorded in the CAS REGISTRY^SM database, Chemical Abstracts Service (CAS) scientists have discovered that a limited number of molecular shapes are the frameworks for a disproportionately large percentage of reported substances.